用阿克拉霉素的联合方案治疗难治性复发性恶性淋巴瘤

The Effect of Combination Treatment of A clacinomycin in Resistant and Relapsed Cases of Malignant Lymphoma

本研究室用阿克拉霉素（ACL）联合方案（AOP或AOP＋Ara－c）治疗难治性复发性恶性淋巴瘤12例（均为非霍奇金淋巴瘤NHL，Ⅰ期1例、Ⅱ期2例、Ⅲ期5例、Ⅳ期4例。）所有病例以往均用CHOP或COP＋米托蒽醌等方案治疗无效或复发，改用本方案后，完全缓解（CR）率达50％，部分缓解（CR）率达33％，总缓解率为83％，证明本方案对难治性复发性恶性淋巴瘤治疗有效；阿克拉霉素与阿霉素（ADM）及米托蒽醌（Mitoxantrone）无交叉耐药性。本文对疗效、毒副作用、缓解疗程及时间等作初步探讨。

The treatment of resistant and relapsed cases of malignant Lymphoma is a difficult clinical problem and is usually unsatisfactory. The authors reported in this paper the treatment of these cases with combined chemotherapy of aclacinomycin (ACL)、 VCR and prednison in twelve cases of malignant lymphoma. All the cases were refractory to the commonly adopted protocol, including CHOP and COP + Mitoxantrone, etc.The result of therapeutic response was good. The complete remission rate in all cases was 50%, PR 33% with a total rate of 83%. It was noted that there was no cross resistance among aclacinomycin、adriamycin and Mitoxantrone. The authors discussed the dosage、duration of the treatmet as well as the side effects of the drug.